Zusammenfassung
Der Einsatz von Heparin, Heparinoiden und Vitamin-K-Antagonisten zur Akutbehandlung bzw. Prävention von Schlaganfällen wird heutzutage kontrovers diskutiert. Bei Vorhofflimmern und -flattern wird eine orale Antikoagulation insbesondere bei Hochrisikopatienten befürwortet. Als weitere Indikationen werden Erkrankungen mit hohem kardialen Embolierisiko (z. B. mechanische Herzklappen und intrakardiale Thromben), symptomatische Dissektionen hirnversorgender Arterien, Basilaris- und Sinusvenen-Thrombose sowie Erkrankungen mit vorwiegend genetisch bedingter Thrombophilie angesehen. Da für viele Befundkonstellationen das Verhältnis von Nutzen und Risiko einer Antikoagulation bislang nicht durch aussagekräftige Studien geklärt ist, sollten therapeutische Entscheidungen unter Berücksichtigung des individuellen Risikoprofils und der spezifischen Pathophysiologie der abgelaufenen zerebralen Ischämie getroffen werden.
Summary
Therapeutic benefit of heparin, heparinoids and Vitamin-K-antagonists in acute stroke as well as in stroke prevention is still a controversial issue. In patients with atrial fibrillation and flutter, oral anticoagulation is recommended when further high risk factors are present. Most experts agree that anticoagulation therapy is useful in disorders with increased cardiogenic embolisation risk (e. g. mechanical valves and intracardiac thrombus), symptomatic dissection of brain-supplying arteries, thrombosis of the basilar artery, sinus venous thrombosis, and in thrombophilia. Since for many clinical constellations controlled randomized studies differentially assessing the benefits and the risks of anticoagulation are lacking, therapeutic decisions have to be based on the patients individual risk profile and pathophysiology of cerebral ischemia.
Literatur
1
Adams H P, Bendixen B H, Leira E. et al .
Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: A report of the Trial of Org 10 172 in Acute Stroke Treatment (TOAST).
Neurology.
1999;
53
122-125
2
Atrial Fibrillation Investigators .
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.
Arch Intern Med.
1994;
154
1449-1457
3
Baker W F, Bick R L.
Treatment of hereditary and acquired thrombophilic disorders.
Semin Thromb Hemost.
1999;
25
387-406
4
Bath P M, Iddenden R, Bath F J.
Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials.
Stroke.
2000;
31
1770-1778
5
Bath P M, Lindenstrom E, Boysen G. et al .
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.
Lancet.
2001;
358
702-710
6
Baumgartner R W, Studer A, Arnold M, Georgiadis D.
Recanalisation of cerebral venous thrombosis.
J Neurol Neurosurg Psychiatry .
2003;
74
459-461
7
Berge E, Abdelnoor M, Nakstad P H, Sandset P M. HAEST Study Group .
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study.
Lancet.
2000;
355
1205-1210
8
Bertram M, Bonsanto M, Hacke W, Schwab S.
Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation.
J Neurol.
2000;
247
209-214
9
Bogousslavsky J, Kaste M, Skyhoj-Olsen T, Hacke W, Orgogozo J M.
Risk factors and stroke prevention.
Cerebrovasc Dis.
2000;
10
(Suppl 3)
12-21
10
Bonow R O, Carabello B, de Leon A C. et al .
Guidelines for the management of patients with valvular heart disease: executive summary.
Circulation.
1998;
98
1949-1984
11
Brandt T, Caplan L.
Spontaneous Arterial Dissection.
Curr Treat Options Neurol.
2001;
3
463-469
12
Cairns J A, Theroux P, Lewis H D, Ezekowitz M, Meade T W.
Antithrombotic agents in coronary artery disease.
Chest.
2001;
119
(Suppl 1)
228S-252S
13
Camerlingo M, Casto L, Censori B. et al .
Immediate anticoagulation with heparin for first-ever ischemic stroke in the carotid artery territories observed within 5 hours of onset.
Arch Neurol.
1994;
51
462-467
14
CAPRIE Steering Committee .
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet.
1996;
348
1329-1339
15
Cerebral Embolism Study Group .
Immediate anticoagulation of embolic stroke: a randomized trial.
Stroke.
1983;
14
668-676
16
Chamorro A, Vila N, Saiz A, Alday M, Tolosa E.
Early anticoagulation after large cerebral embolic infarction: a safety study.
Neurology.
1995;
45
861-865
17
Darius H.
Neue Aspekte zur Antikoagulationsbehandlung bei Vorhofflimmern.
Hämostaseologie.
2002;
22
30-35
18
Diener H C, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A.
European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
J Neurol Sci.
1996;
143
1-13
19
Diener H C, Ringelstein E B, von Kummer R. et al .
Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial.
Stroke.
2001;
32
22-29
20
Dressler F A, Craig W R, Castello R, Labovitz A J.
Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke.
J Am Coll Cardiol.
1998;
31
134-138
21
Droste D W, Freund F, Wichter T. et al .
Paradoxe Hirnembolien als Ursache des Schlaganfalls.
Dtsch Ärztebl.
2002;
99
A281-291
22
Duke R J, Bloch R F, Turpie A G, Trebilcock R, Bayer N.
Intravenous heparin for the prevention of stroke progression in acute partial stable stroke.
Ann Intern Med.
1986;
105
825-828
23
Engelter S T, Lyrer P A, Kirsch E C, Steck A J.
Long-term follow-up after extracranial internal carotid artery dissection.
Eur Neurol.
2000;
44
199-204
24
European stroke prevention study 2 investigators .
European Stroke Prevention Study 2. Efficacy and safety data.
J Neurol Sci.
1997;
151
(Suppl)
S1-77
25
Fuster V, Rydén L E, Asinger R W. et al .
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary.
Circulation.
2001;
104
2118-2150
26
Hacke W, Kaste M, Skyhoj-Olsen T, Bogousslavsky J, Orgogozo J M.
Acute treatment of ischemic stroke.
Cerebrovasc Dis.
2000;
10
(Suppl 3)
22-33
27
Hart R G, Halperin J L.
Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention.
Ann Intern Med.
1999;
131
688-695
28
Hart R G, Halperin J L.
Atrial fibrillation and stroke: concepts and controversies.
Stroke.
2001;
32
803-808
29
Hart R G, Palacio S, Pearce L A.
Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials.
Stroke.
2002;
33
2722-2727
30
Hetzel A.
Stellenwert der Vollheparinisierung bei V.a. akuten thrombembolischen Insult.
Dtsch Med Wochenschr.
2003;
128
569-570
31
International Stroke Trial Collaborative Group .
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19.435 patients with acute ischaemic stroke.
Lancet.
1997;
349
1564-1565
32
Klein E A.
Assessment of cardioversion using transesophageal echocardiography (TEE) multicenter study (ACUTE I): Clinical outcomes at eight weeks.
J Am Coll Cardiol.
2000;
36
324
33
Mas J L, Arquizan C, Lamy C. et al. Patent Foramen Ovale and Atrial Septal Aneurysm Study Group .
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.
N Engl J Med.
2001;
345
1740-1746
34
Mattioli A V, Bonetti L, Aquilina M. et al .
Association between Atrial Septal Aneurysm and Patent Foramen ovale in Young Patients with Recent Stroke and Normal Carotid Arteries.
Cerebrovasc Dis.
2003;
15
4-10
35
Meyer-Lindenberg A, Mewes J, Biniek R.
Megadolichobasilaris als Indikator intensivmedizinisch relevanter vertebrobasilärer Ischämien.
Nervenarzt.
1997;
68
674-677
36
Mohr J P, Thompson J L, Lazar R M. et al .
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
N Engl J Med.
2001;
345
1444-1451
37
Morocutti C, Amabile G, Fattapposta F. et al .
Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation.
Stroke.
1997;
28
1015-1021
38
Overell J R, Bone I, Lees K R.
Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies.
Neurology.
2000;
55
1172-1179
39
Pessin M S, Estol C J, Lafranchise F, Caplan L R.
Safety of anticoagulation after hemorrhagic infarction.
Neurology.
1993;
43
1298-1303
40
Rance A, Emmerich J, Fiessinger J N.
Anticardiolipin antibodies and recurrent thromboembolism.
Thromb Haemost.
1997;
77
221-222
41
Rothwell P M, Eliasziw M, Gutnikov S A. et al .
Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis.
Lancet.
2003;
361
107-116
42
Sacco R L.
Risk factors, outcomes, and stroke subtypes for ischemic stroke.
Neurology.
1997;
49
(Suppl 4)
S39-44
43
Schuchlenz H W, Weihs W, Horner S, Quehenberger F.
The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events.
Am J Med.
2000;
109
456-462
44
Stokman P J, Nandra C S, Asinger R W.
Left Ventricular Thrombus.
Curr Treat Options Cardiovasc Med.
2001;
3
515-521
45
Tatlisumak T, Fisher M.
Hematologic disorders associated with ischemic stroke.
J Neurol Sci.
1996;
140
1-11
46
The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group .
A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin.
Ann Neurol.
1997;
42
857-865
47
Villringer A, Einhäupl K M.
Dural sinus and cerebral venous thrombosis.
New Horiz.
1997;
5
332-341
48
Weih M, Junge-Hülsing J, Mehraein S, Ziemer S, Einhäupl K M.
Hereditäre Thrombophilien bei ischämischem Schlaganfall und Sinusvenenthrombosen.
Nervenarzt.
2000;
71
936-945
49
Weitz J I.
Low-molecular-weight heparins.
N Engl J Med.
1997;
337
688-698
50
Wolf P A, Abbott R D, Kannel W B.
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
Stroke.
1991;
22
983-988
Dr. U. Walter
Klinik und Poliklinik für Neurologie, Universität Rostock
Gehlsheimer Straße 20
18147 Rostock
Phone: 0381/4949696
Fax: 0381/4949512
Email: uwe.walter@med.uni-rostock.de